251 related articles for article (PubMed ID: 36976784)
1. Two decades of pegfilgrastim: what have we learned? Where do we go from here?
De Oliveira Brandao C; Lewis S; Sandschafer D; Crawford J
Curr Med Res Opin; 2023 May; 39(5):707-718. PubMed ID: 36976784
[TBL] [Abstract][Full Text] [Related]
2. A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices.
Rifkin RM; Crawford J; Mahtani RL; Dale DC; Narang M; MacLaughlin WW; Huynh C; Gawade PL; Lewis S; DeCosta L; Lawrence T; Belani R
Support Care Cancer; 2022 Oct; 30(10):7913-7922. PubMed ID: 35732748
[TBL] [Abstract][Full Text] [Related]
3. A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.
Mahtani RL; Belani R; Crawford J; Dale D; DeCosta L; Gawade PL; Huynh C; Lawrence T; Lewis S; MacLaughlin WW; Narang M; Rifkin R
Support Care Cancer; 2022 Jul; 30(7):6135-6144. PubMed ID: 35426046
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
[TBL] [Abstract][Full Text] [Related]
5. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
[No Abstract] [Full Text] [Related]
6. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.
Cooper KL; Madan J; Whyte S; Stevenson MD; Akehurst RL
BMC Cancer; 2011 Sep; 11():404. PubMed ID: 21943360
[TBL] [Abstract][Full Text] [Related]
9. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
[TBL] [Abstract][Full Text] [Related]
10. Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment.
McBride A; MacDonald K; Fuentes-Alburo A; Abraham I
J Med Econ; 2021; 24(1):598-606. PubMed ID: 33866947
[TBL] [Abstract][Full Text] [Related]
11. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.
Morrison VA; Wong M; Hershman D; Campos LT; Ding B; Malin J
J Manag Care Pharm; 2007 May; 13(4):337-48. PubMed ID: 17506600
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
Lyman G; Lalla A; Barron R; Dubois RW
Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
[TBL] [Abstract][Full Text] [Related]
13. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy.
Schenfeld J; Gong T; Henry D; Kelsh M; Gawade P; Peng Y; Bradbury BD; Li S
Support Care Cancer; 2022 Jul; 30(7):6327-6338. PubMed ID: 35482126
[TBL] [Abstract][Full Text] [Related]
14. Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer.
Alrawashdh N; Vraney J; Choi BM; Almutairi AR; Abraham I; McBride A
Future Oncol; 2022 Jun; 18(19):2381-2390. PubMed ID: 35477322
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
Pfeil AM; Allcott K; Pettengell R; von Minckwitz G; Schwenkglenks M; Szabo Z
Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
[TBL] [Abstract][Full Text] [Related]
16. Retrospective Analysis of Clinical Outcomes Associated With the Use of Pegfilgrastim On-body Injector in Patients Receiving Chemotherapy Requiring Granulocyte Colony-Stimulating Factor Support.
Patel J; Rainess RA; Benfield MJ; Rogers KML; Moore DC; Larck C; Arnall JR
Hosp Pharm; 2021 Apr; 56(2):77-80. PubMed ID: 33790481
[No Abstract] [Full Text] [Related]
17. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.
Almenar D; Mayans J; Juan O; Bueno JM; Lopez JI; Frau A; Guinot M; Cerezuela P; Buscalla EG; Gasquet JA; Sanchez J
Eur J Cancer Care (Engl); 2009 May; 18(3):280-6. PubMed ID: 19076208
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.
Gebremariam GT; Fentie AM; Beyene K; Sander B; Gebretekle GB
BMC Health Serv Res; 2022 Dec; 22(1):1600. PubMed ID: 36585648
[TBL] [Abstract][Full Text] [Related]
19. Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Weycker D; Li X; Figueredo J; Barron R; Tzivelekis S; Hagiwara M
Support Care Cancer; 2016 May; 24(5):2309-2316. PubMed ID: 26607482
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a novel medical device for pegfilgrastim administration.
Aruga T; Doihara H; Yanagita Y; Ishida T; Yamashita T; Uehara K; Taira T; Tsurutani J; Takeshita T; Tsuyuki S; Kaneko K; Ohtake T; Yamaguchi Y; Hara Y; Saji S
Cancer Sci; 2022 May; 113(5):1763-1770. PubMed ID: 35293085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
